Adam May on investing in biotech $NKTR $ABVX

The podcast features Adam May, a physician and biotech investor, discussing strategies for identifying alpha in small to mid-cap biotech companies. May emphasizes the importance of high-throughput analysis, focusing on companies with "hair" on them, where investor debates create opportunities. He highlights ABVX, a company with a repurposed drug and an unknown mechanism of action, as an example where analyzing trial nuances revealed potential success. The conversation covers NKTR, where May identified a misanalyzed data set and unmet market needs, leading to significant gains. He also touches on the upcoming maintenance data for ABVX and its potential impact on a possible buyout.